1. Unit startpage
  2. Employees
  3. Pia Abel zur Wiesch
Bilde av Abel zur Wiesch, Pia
Bilde av Abel zur Wiesch, Pia
Computational Pharmacology Computational Pharmacology, Research Group pia.z.wiesch@uit.no

Pia Abel zur Wiesch

Job description

Associate Professor and Early Career Chair, The Pennsylvania State University

Visiting Researcher, Institute for Pharmacy, UiT

Young Associate Investigator, NCMM, Nordic EMBL partnership

 

  • S.V. Leavitt, C.A. Rodriguez, T.C. Bouton, C.R. Horsburgh, Pia Karoline Schulz zur Wiesch Schulz zur Wiesch, B.E. Nichols et al.:
    Outcomes for people with TB by disease severity at presentation
    The International Journal of Tuberculosis and Lung Disease 2024 DOI
  • Antal Martinecz, Martin J. Boeree, Andreas H. Diacon, Rodney Dawson, Colin Hemez, Rob Arnoutse et al.:
    High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance
    PLoS Computational Biology 2023 ARKIV / DOI
  • C.A. Rodriguez, S.V. Leavitt, T.C. Bouton, C.R. Horsburgh, Pia Abel zur Wiesch, B. Nichols et al.:
    Survival of people with untreated TB: effects of time, geography and setting
    The International Journal of Tuberculosis and Lung Disease 2023 DOI
  • Jingyi Liang, Vi Ngoc-Nha Tran, Colin Hemez, Pia Abel zur Wiesch :
    Current Approaches of Building Mechanistic Pharmacodynamic Drug-Target Binding Models
    Springer 2022 DOI
  • Vi Ngoc-Nha Tran, Alireza Shams, Sinan Ascioglu, Antal Martinecz, Jingyi Liang, Fabrizio Clarelli et al.:
    vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding
    BMC Bioinformatics 2022 ARKIV / DOI
  • Colin Hemez, Fabrizio Clarelli, Adam C. Palmer, Christina Bleis, Sören Abel, Leonid Chindelevitch et al.:
    Mechanisms of antibiotic action shape the fitness landscapes of resistance mutations
    Computational and Structural Biotechnology Journal 2022 ARKIV / DOI
  • Irina Kontsevaya, Christoph Lange, Patricia Comella-Del-barrio, Cristian Coarfa, Andrew R. Dinardo, Stephen H. Gillespie et al.:
    Perspectives for systems biology in the management of tuberculosis
    European Respiratory Review 2021 ARKIV / DOI
  • Aaron Nicholas Gillman, Anel Mahmutovic, Pia Abel zur Wiesch, Sören Abel :
    The Infectious Dose Shapes Vibrio Cholerae Within-Host Dynamics
    mSystems 2021 ARKIV / DOI
  • Viacheslav N. Kachalov, Huyen Nguyen, Suraj Balakrishna, Luisa Salazar-Vizcaya, Rami Sommerstein, Stefan P. Kuster et al.:
    Identifying the drivers of multidrug-resistant Klebsiella pneumoniae at a European level
    PLoS Computational Biology 2021 ARKIV / DOI
  • Fabrizio Clarelli, Adam Palmer, Bhupender Singh, Merete Storflor, Silje Lauksund, Ted Cohen et al.:
    Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones
    PLoS Computational Biology 2020 ARKIV / DOI
  • Helen Stagg, Mary Flook, Antal Martinecz, Karina Kielmann, Pia Abel zur Wiesch, Aaron Karat et al.:
    All non-adherence is equal, but is some more equal than others? TB in the digital era.
    European Respiratory Journal Open Research (ERJ Open Research) 2020 ARKIV
  • Anel Mahmutovic, Pia Abel zur Wiesch, Sören Abel :
    Selection or drift: the population biology underlying transposon insertion sequencing experiments.
    Computational and Structural Biotechnology Journal 2020 ARKIV / DOI
  • Helen R. Stagg, Mary Flook, Antal Martinecz, Karina Kielmann, Pia Abel zur Wiesch, Aaron S. Karat et al.:
    All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era
    European Respiratory Journal Open Research (ERJ Open Research) 2020 DOI
  • Antal Martinecz, Fabrizio Clarelli, Sören Abel, Pia Abel zur Wiesch :
    Reaction Kinetic Models of Antibiotic Heteroresistance
    International Journal of Molecular Sciences 2019 ARKIV / DOI
  • Fabrizio Clarelli, Jingyi Liang, Antal Martinecz, Ines Heiland, Pia Abel zur Wiesch :
    Multi-scale modeling of drug binding kinetics to predict drug efficacy
    Cellular and Molecular Life Sciences (CMLS) 2019 ARKIV / DOI
  • Burcu Tepekule, Pia Abel zur Wiesch, Roger D. Kouyos, Sebastian Bonhoeffer :
    Quantifying the impact of treatment history on plasmid-mediated resistance evolution in human gut microbiota
    Proceedings of the National Academy of Sciences of the United States of America (PNAS) 2019 ARKIV / DOI
  • Alyson R. Warr, Troy P. Hubbard, Diana Munera, Carlos J. Blondel, Pia Abel zur Wiesch, Sören Abel et al.:
    Transposon-insertion sequencing screens unveil requirements for EHEC growth and intestinal colonization
    PLoS Pathogens 2019 ARKIV / DOI
  • Antal Martinecz, Pia Abel zur Wiesch :
    Estimating treatment prolongation for persistent infections
    Pathogens and Disease 2018 ARKIV / DOI
  • Ting Zhang, Sören Abel, Pia Abel zur Wiesch, Jumpei Sasabe, Brigid M. Davis, Darren E. Higgins et al.:
    Deciphering the landscape of host barriers to Listeria monocytogenes infection
    Proceedings of the National Academy of Sciences of the United States of America (PNAS) 2017 ARKIV / DOI
  • Pia Abel zur Wiesch, Fabrizio Clarelli, Ted Cohen :
    Using chemical reaction kinetics to predict optimal antibiotic treatment strategies
    PLoS Computational Biology 2017 ARKIV / DOI
  • Amber Kunkel, Pia Abel zur Wiesch, Ruvandhi R. Nathavitharana, Florian M. Marx, Helen E. Jenkins, Ted Cohen :
    Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis
    BMC Infectious Diseases 2016 DOI
  • Troy Hubbard, Michael C Chao, Sören Abel, Carlos J Blondel, Pia Abel zur Wiesch, Xiaohui Zhou et al.:
    Genetic analysis of vibrio parahaemolyticus intestinal colonization
    Proceedings of the National Academy of Sciences of the United States of America (PNAS) 2016 DOI
  • Dominique Cadosch, Pia Abel zur Wiesch, Roger Kouyos, Sebastian Bonhoeffer :
    The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB
    PLoS Computational Biology 2016 ARKIV / DOI
  • Sören Abel, Pia Karoline Abel-Zur Wiesch Genannt Hülsho, Hsiao-Han Chang, Brigid M. Davis, Marc Lipstich, Matthew K. Waldor :
    Sequence tag-based analysis of microbial population dynamics
    Nature Methods 2015 DOI
  • Sören Abel, Pia Schulz Zur Wiesch, Brigid M. Davis, Matthew K. Waldor :
    Analysis of Bottlenecks in Experimental Models of Infection
    PLoS Pathogens 2015 ARKIV / DOI
  • Pia Abel zur Wiesch, Sören Abel, Spyridon Gkotzis, Paolo Ocampo, Jan Engelstädter, Trevor Hinkley et al.:
    Classic reaction kinetics can explain complex patterns of antibiotic action
    Science Translational Medicine 2015 DOI
  • Pia Karoline Abel-Zur Wiesch Genannt Hülsho, Roger D. Kouyos, Sören Abel, Wolfgang Viechtbauer, Sebastian Bonhoeffer :
    Cycling empirical antibiotic therapy in hospitals: meta-analysis and models
    PLoS Pathogens 2014 DOI
  • Sören Abel, Tabitha Bucher, Micael Nicollier, Isabelle Hug, Volkhard Kaever, Pia Karoline Abel-Zur Wiesch Genannt Hülsho et al.:
    Bi-modal distribution of the second messenger c-di-GMP controls cell fate and asymmetry during the caulobacter cell cycle
    PLoS Genetics 2013 DOI
  • Niklas Koehler, Sönke Andres, Matthias Merker, Viola Dreyer, Agnieszka John, Martin Kuhns et al.:
    Pretomanid-resistant tuberculosis
    Journal of Infection 2023 DOI
  • Anel Mahmutovic, Aaron Nicholas Gillman, Silje Lauksund, Natasha-Anne Robson Moe, Aimé Manzi, Merete Storflor et al.:
    RESTAMP – Rate estimates by sequence-tag analysis of microbial populations
    Computational and Structural Biotechnology Journal 2021 ARKIV / DOI
  • Vi Ngoc-Nha Tran, Alireza Shams, Sinan Ascioglu, Antal Martinecz, Jingyi Liang, Fabrizio Clarelli et al.:
    vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding
    2020 FULLTEKST
  • Pia Abel zur Wiesch, Antal Martinecz :
    Mathematical Models of Optimal Antibiotic Treatment
    UiT Norges arktiske universitet 2020
  • Antal Martinecz, Martin J. Boeree, Andreas H. Diacon, Rodney Dawson, Rob E. Aarnoutse, Pia Abel zur Wiesch :
    High peak drug concentrations increase the bactericidal action in the slow phase of bacterial elimination in EBA trials of tuberculosis patients. Conference presentation at "2nd Arctic Meeting on Clinical Tuberculosis"
    2019
  • Antal Martinecz, Martin J. Boeree, Andreas H. Diacon, Rodney Dawson, Rob E. Aarnoutse, Pia Abel zur Wiesch :
    High peak rifampicin plasma concentrations accelerate the slow phase of bacterial elimination in tuberculosis patients
    2019
  • Pia Abel zur Wiesch :
    How to design dosing strategies
    2019
  • Pia Abel zur Wiesch :
    How to design antibiotic dosing strategies in tuberculosis
    2019
  • Pia Abel zur Wiesch, Natasha-Anne Robson Moe, Silje Lauksund, Antal Martinecz :
    Bacterial replication and death rates during exposure to bactericidal antibiotics
    UiT Norges arktiske universitet 2019
  • Pia Abel zur Wiesch :
    How to design antibiotic dosing strategies
    2019
  • Fabrizio Clarelli, Bhupender Singh, Adam Palmer, Sören Abel, Ted Cohen, Pia Abel zur Wiesch :
    Quantitatively predicting antibiotic susceptibility from biochemical parameters: implications for antibiotic development and preventing resistance
    2018
  • Antal Martinecz, Pia Abel zur Wiesch, Roland R. Regoes :
    Within Host Infection Dynamics: Persisters can infect new sites and cause relapse if the immune clearance is low
    2018
  • Fabrizio Clarelli, Ted Cohen, Sören Abel, Bhupender Singh, Adam Palmer, Leonid Chindelevitch et al.:
    How molecular mechanisms of resistance affect resistance evolution
    2018
  • Fabrizio Clarelli, Bhupender Singh, Ted Cohen, Adam Palmer, Leonid Chindelevitch, Sören Abel et al.:
    Using models to understand how molecular mechanisms of resistance affect the risk of acquired drug resistance during treatment
    2018
  • Antal Martinecz, Martin J. Boeree, Andreas H. Diacon, Rodney Dawson, Rob E. Aarnoutse, Pia Abel zur Wiesch :
    High peak drug concentrations increase the bactericidal action in the slow phase of bacterial elimination in EBA trials of tuberculosis patients. Conference presentation at "International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2018" The Hague, Netherlands
    2018
  • Pia Abel zur Wiesch :
    How to design dosing strategies
    2018
  • Antal Martinecz, Pia Abel zur Wiesch, Roland Regoes :
    Persistence lengthens the treatment of chronic infections
    2018
  • Antal Martinecz, Martin J. Boeree, Andreas H. Diacon, Rodney Dawson, Rob E. Aarnoutse, Pia Abel zur Wiesch :
    High peak drug concentrations increase the bactericidal action in the slow phase of bacterial elimination in EBA trials of tuberculosis patients
    2018
  • Pia Abel zur Wiesch :
    At the interface of chemical kinetics and population biology: how to design antibiotic dosing strategies in tuberculosis
    2018
  • Fabrizio Clarelli, Leonid Chindelevitch, Bhupender Singh, Ted Cohen, Sören Abel, Pia Abel zur Wiesch :
    Using models to understand how molecular mechanisms of resistance affect the risk of acquired drug resistance during treatment
    2017
  • Pia Abel zur Wiesch, Ted Cohen, Rafał Mostowy, Alireza Shams :
    Predicting Antibiotic Pharmacodynamics Using Chemical Kinetics
    2017 DATA / FULLTEKST

    • The 50 latest publications is shown on this page. See all publications in Cristin here →

    Publications outside Cristin

    A Kunkel*, P Abel zur Wiesch*, RR Nathavitharana, FM Marx, HE Jenkins, T Cohen

    BMC infectious diseases 16 (1), 282

    Hubbard PT, Chao MC, Abel S, Blondel CJ, Abel zur Wiesch P, Zhou X, Davis BM, and Waldor MK.
    PNAS (2016) published ahead of print doi:10.1073/pnas.1601718113.

    Cadosch D, Abel zur Wiesch P, Kouyos RD, and Bonhoeffer, S.
    PLOS Computational Biology (2016) 12 (3):e1004749.

    Salvatore P, Becerra M, Abel zur Wiesch P, Hinkley T, Kaur D, Sloutsky A, Cohen T
    Fitness costs of drug-resistance mutations in multidrug resistant M. tuberculosis: a household-based case-control study.
    J. Infect. Dis. (2015) pii: jiv347. [Epub ahead of print]

    Abel S, Abel zur Wiesch P, Davis BM, and Waldor MK
    Analysis of bottlenecks in experimental models of infection.
    PLOS PATHOGENS (2015) 11(6):e1004823

    Abel zur Wiesch P#, Abel S, Gkotzis S, Ocampo P, Engelstädter J, Hinkley T, Magnus C, Waldor MK, Udekwu K, and Cohen T
    Classic reaction kinetics can explain complex patterns of antibiotic action.
    SCI. TRANSL. MED. (2015) 7(287):287ra73    

    Abel S, Abel zur Wiesch P, Chang H-H, Davis BM, Lipsitch M, and Waldor MK
    Sequence tag-based analysis of pathogen population dynamics.
    Nature Methods (2015) 12(3):223-6

    Kouyos RD, Metcalf CJE, Birger R, Klein EY, Abel zur Wiesch P, Ankomah P, et al.
    The path of least resistance: aggressive or moderate treatment?
    Proceedings of the Royal Society B: Biological Sciences (2014) 281(1794):20140566

    Ocampo PS, Lazar V, Bogos B, Arnoldini M, Abel zur Wiesch P, Busa-Fekete R, Fekete G, Pal C, Ackermann M and Bonhoeffer S
    Antagonism is prevalent between bacteriostatic and bactericidal antibiotics.
    Antimicrobial Agents and Chemotherapy (2014) 58(8):4573-82

    Abel zur Wiesch P#*, Kouyos RD*, Abel S, Viechtbauer W, and Bonhoeffer S
    Optimal antibiotic treatment in hospitals: meta-analysis and models.
    PLOS Pathogens (2014) 10(6):e1004225

    Abel S, Bucher T, Nicollier M, Hug I, Kaever V, Abel zur Wiesch P, Jenal U
    Bi-modal Distribution of the Second Messenger c-di-GMP Controls Cell Fate and Asymmetry during the Caulobacter Cell Cycle.
    PLOS Genetics (2013) 9(9):e1003744

     

    Kouyos RD*, Abel zur Wiesch P*, Bonhoeffer S
    On being the right size: the impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community.
    PLOS Pathogens (2011) 7(4):e1001334.

    Kouyos RD, Abel zur Wiesch P, Bonhoeffer S
    Informed Switching Strongly Decreases the Prevalence of Antibiotic Resistance in Hospital Wards.
    PLOS Computational Biology (2011) 7(3):e1001094.

    Abel zur Wiesch P*, Kouyos R*, Engelstädter J, Regoes R, Bonhoeffer S
    Population biological principles of resistance evolution in infectious diseases.
    Lancet Infectious Diseases (2011) 11(3):236-247.

    Bonhoeffer S, Abel zur Wiesch P, and Kouyos RD
    Rotating antibiotics does not minimize selection for resistance.
    Mathematical Biosciences and Engineering (2010) 7(4):919-922.

    Schulz zur Wiesch P#, Engelstädter J, and Bonhoeffer S
    Compensation of Fitness Costs and Reversibility of Antibiotic Resistance Mutations.
    Antimicrobial Agents and Chemotherapy (2010) 54(5):2085-95

    Research interests

    Antibiotics, Population Biology, Biochemistry, Pharmacology, Tuberculosis, Infectious Diseases,Public Health, Mathematical Modelling